{ "labelLang" : "eng", "responseDate" : "2024-03-29 07:49", "content" : { "otype" : "JournalArticle", "mtid" : 32097729, "status" : "APPROVED", "published" : true, "comment" : "Export Date: 9 May 2022 \n CODEN: LAMEF \n Correspondence Address: Zoltán, B.; University of Debrecen, Nagyerdei körút 98, Hungary; email: baloghz@belklinika.com", "unhandledTickets" : 0, "deleted" : false, "lastRefresh" : "2024-01-08T12:53:42.560+0000", "lastModified" : "2022-06-14T08:51:16.897+0000", "created" : "2021-07-08T13:00:09.012+0000", "creator" : { "otype" : "Admin", "mtid" : 10028537, "link" : "/api/admin/10028537", "label" : "Gabriella Baczkó (SZTE ÁOK admin5 Reuma és Farmakológia)", "familyName" : "Baczkó", "givenName" : "Gabriella", "published" : true, "oldId" : 10028537, "snippet" : true }, "lastDuplumOK" : "2023-07-25T11:59:25.751+0000", "lastDuplumSearch" : "2023-07-25T11:59:25.751+0000", "core" : true, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Journal Article", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 10000059, "link" : "/api/subtype/10000059", "label" : "Article (Journal Article)", "name" : "Szakcikk", "nameEng" : "Article", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Journal Article", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 101, "published" : true, "oldId" : 10000059, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Scientific", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10001, "link" : "/api/language/10001", "label" : "Hungarian", "name" : "Magyar", "nameEng" : "Hungarian", "published" : true, "oldId" : 1, "snippet" : true } ], "firstAuthor" : "Zoltán, Balogh", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 96774369, "link" : "/api/authorship/96774369", "label" : "Zoltán, Balogh ✉ [Balogh, Zoltán (belgyógyászat), author] Belgyógyászati Intézet (UD)", "listPosition" : 1, "share" : 0.5, "first" : true, "last" : false, "corresponding" : true, "author" : { "otype" : "Author", "mtid" : 10040349, "link" : "/api/author/10040349", "label" : "Zoltán Balogh (belgyógyászat)", "familyName" : "Balogh", "givenName" : "Zoltán", "published" : true, "oldId" : 10040349, "snippet" : true }, "familyName" : "Zoltán", "givenName" : "Balogh", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Author", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 96774370, "link" : "/api/authorship/96774370", "label" : "Lívia, Sira", "listPosition" : 2, "share" : 0.5, "first" : false, "last" : true, "corresponding" : false, "familyName" : "Lívia", "givenName" : "Sira", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Author", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true } ], "title" : "Benefits of SGLT-2 inhibitors: Beyond glycemic control", "altTitles" : "Az SGLT-2-gátlók haszna: Túl a glykaemiás hatáson", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 18997806, "link" : "/api/publicationidentifier/18997806", "label" : "DOI: 10.33616/LAM.31.005", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.33616/LAM.31.005", "realUrl" : "https://doi.org/10.33616/LAM.31.005", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 18997805, "link" : "/api/publicationidentifier/18997805", "label" : "Scopus: 85107675877", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "85107675877", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85107675877", "published" : false, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 1216892, "link" : "/api/journal/1216892", "label" : "LEGE ARTIS MEDICINAE 0866-4811 2063-4161", "pIssn" : "0866-4811", "eIssn" : "2063-4161", "reviewType" : "REVIEWED", "noIF" : true, "sciIndexed" : false, "scopusIndexed" : true, "lang" : "HUNGARIAN", "hungarian" : true, "published" : true, "oldId" : 1216892, "snippet" : true }, "volume" : "31", "issue" : "3-4", "firstPage" : "89", "lastPage" : "97", "firstPageOrInternalIdForSort" : "89", "pageLength" : 9, "publishedYear" : 2021, "abstractText" : "In the recent years, according to international and Hungarian guidelines, in addition to lifestyle modification, metformin is the preferred initial glucose-lowering drug for most people with type 2 diabetes, if not contraindicated. Sodium glucose co-transporter-2 inhibitors have been shown to reduce progression of chronic kidney disease, or kidney failure, as well as the risk of hospitalizations for congestive heart failure and (mainly in secondary prevention) cardiovascular death in patients with type 2 diabetes. For major adverse cardiovascular events and for the renoprotection, there seems to be no class effect. On the other hand, a class effect of sodium glucose co-transporter-2 inhibitors is evident for hospitalization for heart failure. In this review the authors summarize novel data about sodium glucose cotransporter-2 inhibitors, and about their new perspectives in the near future. © 2021 Literatura Medica Publishing House. All rights reserved.", "keywords" : [ { "otype" : "Keyword", "mtid" : 14373, "link" : "/api/keyword/14373", "label" : "chronic kidney disease", "published" : true, "oldId" : 14373, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1036146, "link" : "/api/keyword/1036146", "label" : "congestive heart failure", "published" : true, "oldId" : 1036146, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1500463, "link" : "/api/keyword/1500463", "label" : "SGLT-2 inhibitors", "published" : true, "snippet" : true } ], "digital" : null, "printed" : null, "sourceYear" : 2021, "foreignEdition" : false, "foreignLanguage" : false, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : true, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2024-01-08", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "nationalOriginCitationCount" : 0, "foreignEditionCitationCount" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "wosScopusCitationCount" : 0, "wosScopusCitationCountWoOther" : 0, "wosScopusIndependentCitationCount" : 0, "wosScopusIndependentCitationCountWoOther" : 0, "independentCitationCount" : 0, "selfCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "citingPubCountWoOther" : 0, "independentCitingPubCountWoOther" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 7, "citedCount" : 7, "ratings" : [ { "otype" : "SjrRating", "mtid" : 11396849, "link" : "/api/sjrrating/11396849", "label" : "sjr:Q4 (2021) Scopus - Medicine (miscellaneous) LEGE ARTIS MEDICINAE 0866-4811 2063-4161", "listPos" : 2397, "rankValue" : 1.0, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 2701, "link" : "/api/classificationexternal/2701", "label" : "Scopus - Medicine (miscellaneous)", "published" : true, "oldId" : 2701, "snippet" : true }, "ranking" : "Q4", "calculation" : "DIRECT", "published" : true, "snippet" : true } ], "ratingsForSort" : "Q4", "references" : [ { "otype" : "Reference", "mtid" : 21674716, "link" : "/api/reference/21674716", "label" : "1. Balogh, Z, Sira, L., Cukorbetegek perioperatív antihypergly-kaemiás kezelése (2020) Metabolizmus, 18, pp. 202-207", "listPosition" : 1, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674715, "link" : "/api/reference/21674715", "label" : "2. Jermendy, Gy, Wittmann, I., (2019) SGLT-2 gátlók a diabetológiai gyakorlatban, , Budapest: Medicina Könyvkiadó Zrt", "listPosition" : 2, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674714, "link" : "/api/reference/21674714", "label" : "3. Sumida, Y, Yoneda, M, Tokushige, K, Kawanaka, M, Fujii, H, Yoneda, M, Antidiabetic Therapy in the treatment of nonalcoholic steatohepatitis (2020) Int J Mol Sci, , https://doi.org/10.3390/ijms21061907", "listPosition" : 3, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674713, "link" : "/api/reference/21674713", "label" : "4. Verma, S, Jüni, P, Mazer, CD., Pump, pipes, and filter: Do SGLT2 inhibitors cover it all? (2019) Lancet, 393, pp. 3-5. , https://doi.org/10.1016/S0140-6736(18)32824-1", "listPosition" : 4, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674712, "link" : "/api/reference/21674712", "label" : "5. Cosentino, F, Grant, PJ, Aboyans, V, Bailey, CJ, Ceriello, A, Delgado, V, 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) (2020) Eur Heart J, 41, pp. 255-323", "listPosition" : 5, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674711, "link" : "/api/reference/21674711", "label" : "6. Verma, S, Anker, SD, Butler, J, Bhatt, DL., Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST WHF in perspective (2020) ESC Heart Fail, 7, pp. 3261-3267. , https://doi.org/10.1002/ehf2.13148", "listPosition" : 6, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674710, "link" : "/api/reference/21674710", "label" : "7. Butler, J, Usman, MS, Khan, MS, Greene, SJ, Friede, T, Vaduganathan, M, Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta analysis (2020) ESC Heart Fail, 7, pp. 3298-3309. , https://doi.org/10.1002/ehf2.13169", "listPosition" : 7, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674709, "link" : "/api/reference/21674709", "label" : "8. McGuire, DK, Shih, WJ, Cosentino, F, Charbonnel, B, Cherney, DZJ, Dagogo-Jack, S, Association of SGLT-2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis (2021) JAMA Cardiol, 6, pp. 1-11. , https://doi.org/10.1001/jamacardio.2020.4511", "listPosition" : 8, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674708, "link" : "/api/reference/21674708", "label" : "9. Zelniker, TA, Wiviott, SD, Raz, I, Im, K, Goodrich, EL, Bonaca, M P, SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2019) Lancet, 393, pp. 31-39. , https://doi.org/10.1016/S0140-6736(18)32590-X", "listPosition" : 9, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674707, "link" : "/api/reference/21674707", "label" : "10. Bhatt, DL, Szarek, M, Pitt, B, Cannon, C P, Leiter, LA, McGuire, DK, Sotagliflozin in patients with diabetes and chronic kidney disease (2021) N Engl J Med, 384, pp. 129-139. , https://doi.org/10.1056/NEJMoa2030183, for the SCORED Investigators", "listPosition" : 10, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674706, "link" : "/api/reference/21674706", "label" : "11. Zannad, F, Ferreira, J P, Pocock, SJ, Anker, SD, Butler, J, Filippatos, G, SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of The EMPEROR-Reduced and DAPA-HF trials (2020) Lancet, 396, pp. 819-829. , https://doi.org/10.1016/S0140-6736(20)31824-9", "listPosition" : 11, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674705, "link" : "/api/reference/21674705", "label" : "12. Packer, M, Anker, SD, Butler, J, Filippatos, G, Pocock, SJ, Carson, P, Cardiovascular and Renal outcomes with empagliflozin in heart failure (2020) N Engl J Med, 383, pp. 1413-1424. , https://doi.org/10.1056/NEJMoa2022190", "listPosition" : 12, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674704, "link" : "/api/reference/21674704", "label" : "13. Heerspink, HJL, Stefánsson, BV, Correa-Rotter, R, Chertow, GM, Greene, T, Hou, F F, Dapagliflozin in patients with chronic kidney disease (2020) N Engl J Med, 383, pp. 1436-1446. , https://doi.org/10.1056/NEJMoa2024816", "listPosition" : 13, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674703, "link" : "/api/reference/21674703", "label" : "14. Kaplinsky, E., DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure (2020) Drugs in Context, 9, pp. 2019-11. , https://doi.org/10.7573/dic.2019-11-3, 3", "listPosition" : 14, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674702, "link" : "/api/reference/21674702", "label" : "15. McMurray, JJV, Solomon, SD, Inzucchi, SE, Køber, L, Kosiborod, MN, Martinez, F, Dapagliflozin in patients with heart failure and reduced ejection fraction (2019) N Engl J Med, 381, pp. 1995-2008. , https://doi.org/10.1056/NEJMoa1911303", "listPosition" : 15, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674701, "link" : "/api/reference/21674701", "label" : "16. Zelniker, TA, Braunwald, E., Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review (2020) J Am Coll Cardiol, 75, pp. 422-434. , https://doi.org/10.1016/j.jacc.2019.11.031", "listPosition" : 16, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674700, "link" : "/api/reference/21674700", "label" : "17. Seferović, PM, Petrie, MC, Filippatos, GS, Anker, SD, Rosano, G, Bauersachs, J, Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology (2018) Eur J Heart Fail, 20, pp. 853-872. , https://doi.org/10.1002/ejhf.1170", "listPosition" : 17, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674699, "link" : "/api/reference/21674699", "label" : "18. Kannel, WB, Hjortland, M, Castelli, WP., Role of diabetes in congestive heart failure: the Framingham study (1974) Am J Cardiol, 34, pp. 29-34. , https://doi.org/10.1016/0002-9149(74)90089-7", "listPosition" : 18, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674698, "link" : "/api/reference/21674698", "label" : "19. Schernthaner, G, Karasik, A, Abraitien, A, Ametov, AS, Gaàl, Zs, Gumprecht, J, Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs (2019) Cardiovasc Diabetol, 18, p. 115. , https://doi.org/10.1186/s12933-019-0920-3, Published online 2019 Aug 31", "listPosition" : 19, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674697, "link" : "/api/reference/21674697", "label" : "20. Kosiborod, M, Cavender, MA, Fu, AZ, Wilding, J P, Khunti, K, Holl, RH, Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 In hibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardio vas cular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors) (2017) Circulation, 136, pp. 249-259. , https://doi.org/10.1161/CIRCULATIONAHA.117.029190", "listPosition" : 20, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674696, "link" : "/api/reference/21674696", "label" : "21. Giugliano, D, Longo, M, Scappaticcio, L, Caruso, P, Esposito, K., Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes Cardiovasc Diabetol, p. 17. , https://doi.org/10.1186/s12933-021-01213-w, 202120:. Published online 2021 Jan 11", "listPosition" : 21, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674695, "link" : "/api/reference/21674695", "label" : "22. Cosentino, F, Cannon, C P, Cherney, DZI, Masiukiewicz, U, Pratley, R, Dagogo-Jack, S, Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial (2020) Circulation, 142, pp. 2205-2215. , https://doi.org/10.1161/CIRCULATIONAHA.120.050255", "listPosition" : 22, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674694, "link" : "/api/reference/21674694", "label" : "23. Cannon, C P, Pratley, R, Dagogo-Jack, S, Mancuso, J, Huyck, S, Masiukiewicz, U, Cardiovascular outcomes with ertugliflozin in type 2 diabetes (2020) N Engl J Med, 383, pp. 1425-1435. , https://doi.org/10.1056/NEJMoa2004967", "listPosition" : 23, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674693, "link" : "/api/reference/21674693", "label" : "24. Perkovic, V, Jardine, MJ, Neal, B, Bompoint, S, Heerspink, HJL, Charytan, DM, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (2019) N Engl J Med, 380, pp. 2295-2306. , https://doi.org/10.1056/NEJMoa1811744, CREDENCE Trial Investigators", "listPosition" : 24, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674692, "link" : "/api/reference/21674692", "label" : "25. Neal, B, Perkovic, V, Mahaffey, K W, de Zeeuw, D, Fulcher, G, Erondu, N, Canagliflozin and cardiovascular and renal events in type 2 diabetes (2017) N Engl J Med, 377, pp. 644-657. , https://doi.org/10.1056/NEJMoa1611925, CANVAS Program Collaborative Group", "listPosition" : 25, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674691, "link" : "/api/reference/21674691", "label" : "26. Wiviott, SD, Raz, I, Bonaca, M P, Mosenzon, O, Kato, ET, Cahn, A, Dapagliflozin and cardiovascular outcomes in type 2 diabetes (2019) N Engl J Med, 380, pp. 347-357. , https://doi.org/10.1056/NEJMoa1812389, DECLARE-TIMI 58 Investigators", "listPosition" : 26, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674690, "link" : "/api/reference/21674690", "label" : "27. Zinman, B, Wanner, C, Lachin, JM, Fitchett, D, Bluhmki, E, Hantel, S, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (2015) N Engl J Med, 373, pp. 2117-2128. , https://doi.org/10.1056/NEJMoa1504720", "listPosition" : 27, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674689, "link" : "/api/reference/21674689", "label" : "28. Standards of Medical Care in Diabetes-2021. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021 (2021) Diabetes Care, 44, pp. S125-S150. , https://doi.org/10.2337/dc21-S010, American Diabetes Association. (Supplement 1)", "listPosition" : 28, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674688, "link" : "/api/reference/21674688", "label" : "29. Buse, JB, Wexler, DJ, Tsapas, A, Rossing, P, Mingrone, G, Mathieu, C, 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the Ame rican Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2020) Diabetologia, 63, pp. 221-228. , https://doi.org/10.1007/s00125-019-05039-w", "listPosition" : 29, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674687, "link" : "/api/reference/21674687", "label" : "30. Schernthaner, G, Drexel, H, Moshkovich, E, Zilaitiene, B, Martinka, E, Czupryniak, L, SGLT2 inhibitors in T2D and as sociated comorbidities - differentiating within the class (2019) BMC Endocr Disord, 19, p. 64. , https://doi.org/10.1186/s12902-019-0387-y", "listPosition" : 30, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 21674686, "link" : "/api/reference/21674686", "label" : "31. Hamada, S, Gulliford, MC., Multiple risk factor control, mortality and cardiovascular events in type 2 diabetes and chronic kidney disease: a population-based cohort study (2018) BMJ Open, 8, p. e019950. , https://doi.org/10.1136/bmjopen-2017-019950", "listPosition" : 31, "published" : false, "snippet" : true } ], "hasCitationDuplums" : false, "inSelectedPubs" : "10040349", "userChangeableUntil" : "2021-10-06T13:01:30.727+0000", "directInstitutesForSort" : "Belgyógyászati Intézet (DE / ÁOK); LAM szerkesztősége (Kiadók / Önkéntes)", "ownerAuthorCount" : 1, "ownerInstituteCount" : 13, "directInstituteCount" : 2, "authorCount" : 2, "contributorCount" : 0, "hasQualityFactor" : false, "link" : "/api/publication/32097729", "label" : "Zoltán Balogh et al. Benefits of SGLT-2 inhibitors: Beyond glycemic control. (2021) LEGE ARTIS MEDICINAE 0866-4811 2063-4161 31 3-4 89-97", "template" : "